Eurand N.V. (EURX) - NASDAQ
EURX is defunct.
  • Dec. 1, 2010, 8:33 AM

    Specialty pharmaceutical firm Eurand (EURX) agrees to be bought for $12/share in cash by Axcan holdings, a pharma firm focused on gastrointestinal disorders. The $583M deal is a 9% premium to Eurand's close yesterday. (PR)

    | Dec. 1, 2010, 8:33 AM
Company Description
Currently, there's no company description for EURX.
Sector: Healthcare
Industry: Biotechnology
Country: United States